1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting
(
- Contribution to journal › Article
- 2016
-
Mark
In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
(
- Contribution to journal › Article
-
Mark
Genetic Predisposition to Poor Opioid Response in Preterm Infants : Impact of KCNJ6 and COMT Polymorphisms on Pain Relief after Endotracheal Intubation
(
- Contribution to journal › Article
- 2011
-
Mark
The Role of Inosine-5'-Monophosphate Dehydrogenase in Thiopurine Metabolism in Patients With Inflammatory Bowel Disease.
(
- Contribution to journal › Article
- 2007
-
Mark
Therapeutic drug monitoring of escitalopram in an outpatient setting
(
- Contribution to journal › Article
- 2005
-
Mark
Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder - A 6-month therapeutic drug monitoring study
(
- Contribution to journal › Article
- 2004
-
Mark
Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population.
(
- Contribution to journal › Article
- 2003
-
Mark
Therapeutic Drug Monitoring of Racemic Citalopram: A 5-Year Experience in Sweden, 1992-1997.
(
- Contribution to journal › Article
- 2002
-
Mark
Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
(
- Contribution to journal › Article
-
Mark
Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
(
- Contribution to journal › Article